Share on StockTwits

Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) was upgraded by research analysts at Argus from a “hold” rating to a “buy” rating in a report released on Friday, TheFlyOnTheWall.com reports. The firm currently has a $58.00 price target on the stock. Argus’ target price suggests a potential upside of 13.84% from the stock’s previous close. The analysts noted that the move was a valuation call.

Shares of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) opened at 50.95 on Friday. Teva Pharmaceutical Industries Ltd has a 52 week low of $36.26 and a 52 week high of $54.70. The stock has a 50-day moving average of $50.40 and a 200-day moving average of $46.35. The company has a market cap of $43.343 billion and a price-to-earnings ratio of 31.47. Teva Pharmaceutical Industries Ltd also was the recipient of some unusual options trading activity on Wednesday. Investors bought 5,281 put options on the company. This represents an increase of approximately 111% compared to the average volume of 2,505 put options.

Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last announced its earnings results on Thursday, May 1st. The company reported $1.22 earnings per share for the quarter, meeting the analysts’ consensus estimate of $1.22. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $5.11 million. During the same quarter last year, the company posted $1.12 earnings per share. Teva Pharmaceutical Industries Ltd’s revenue was up 2.0% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries Ltd will post $4.70 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Monday. They now have a $53.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Friday, May 16th. They now have a $61.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Thursday, May 8th. They now have a $61.00 price target on the stock. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries Ltd presently has a consensus rating of “Buy” and a consensus target price of $56.36.

Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is an Israel-based pharmaceutical and drug company.

The Fly On The Wall

Receive News & Ratings for Teva Pharmaceutical Industries Ltd (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.